PGR and breast neoplasm: In luminal breast tumors, characterized by estrogen receptor (ER) and/or progesterone receptor (PR) expression, mutations in enhancers and promoters of hormone-responsive genes, such as FOXA1 and ESR1, can disrupt hormone signaling, leading to endocrine therapy resistance [17,18].